

Special Issue

Novel HIV Immunization Regimens and Immune Implications

Message from the Guest Editors

The elicitation of a protective immune response is the goal of vaccine research for HIV-1 and other pathogens. Novel vaccine platforms, such as nanoparticles, virus-like particles (VLPs), and mRNA LNP platforms, combined with new adjuvants and immunization regimens, have provided promising approaches to vaccine development for emerging disease pathogens and for difficult-to-achieve vaccines. Understanding the implication of vaccine-elicited immune response with these new immunogens/regimens will move the field forward and help the evaluation and development of more effective vaccine products. Manuscripts reporting on new HIV-1 immunogens, novel immunization regimens, immune response analysis with new antigens and methods, immune response monitoring, and new animal models are welcome for this Special Issue. This Special Issue encourages the submission of original articles, systematic reviews, meta-analyses, short communications, and other types of articles that describe the application of new immunogens and immunization regimens, or the association of immune responses to vaccine outcomes.

Guest Editors

Dr. Hongying Duan

Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA

Dr. Rui Kong

Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA

Deadline for manuscript submissions

closed (31 May 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/194678

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).